FY2024 EPS Estimates for TSE:BHC Raised by Analyst

Bausch Health Companies Inc. (TSE:BHC) – Equities research analysts at Zacks Research upped their FY2024 earnings per share (EPS) estimates for Bausch Health Companies in a research report issued to clients and investors on Tuesday, December 17th. Zacks Research analyst R. Department now forecasts that the company will post earnings per share of $5.33 for the year, up from their previous estimate of $5.21. The consensus estimate for Bausch Health Companies’ current full-year earnings is $5.55 per share. Zacks Research also issued estimates for Bausch Health Companies’ Q4 2024 earnings at $1.60 EPS, Q1 2025 earnings at $1.22 EPS, Q2 2025 earnings at $1.47 EPS, Q3 2025 earnings at $1.65 EPS, FY2025 earnings at $6.13 EPS, Q1 2026 earnings at $1.56 EPS, Q2 2026 earnings at $1.63 EPS, Q3 2026 earnings at $1.96 EPS and FY2026 earnings at $7.23 EPS.

Separately, Evercore ISI raised shares of Bausch Health Companies to a “hold” rating in a report on Tuesday, October 15th.

Bausch Health Companies Stock Up 0.5 %

BHC stock opened at C$10.64 on Thursday. The company has a debt-to-equity ratio of 7,583.76, a current ratio of 1.19 and a quick ratio of 0.58. The firm’s fifty day simple moving average is C$11.67 and its 200-day simple moving average is C$9.94. Bausch Health Companies has a 12 month low of C$5.45 and a 12 month high of C$15.43. The company has a market capitalization of C$3.91 billion, a P/E ratio of -6.08, a price-to-earnings-growth ratio of 0.21 and a beta of 0.77.

Bausch Health Companies (TSE:BHC) last released its earnings results on Wednesday, October 30th. The company reported C$1.53 earnings per share (EPS) for the quarter, beating the consensus estimate of C$1.43 by C$0.10. Bausch Health Companies had a negative return on equity of 2,304.54% and a negative net margin of 5.12%. The firm had revenue of C$3.42 billion for the quarter, compared to the consensus estimate of C$3.36 billion.

About Bausch Health Companies

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.